[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616566":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":28,"responsibleParty":47,"collaborators":11,"id":49,"slug":11,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Syntis Bio","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Drug SYNT101","ACTIVE_COMPARATOR",null,[13],"Drug: SYNT101",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","SYNT101","Tablet",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo tablet to match SYNT101 in appearance.",[15],[29],{"facility":30,"status":31,"city":32,"state":33,"zip":11,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Veritus Research","RECRUITING","Bayswater","Victoria","Australia",{"type":36,"coordinates":37},"Point",[38,39],145.26667,-37.85,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":45,"phoneExt":11,"email":46},"Rebecca Wolf","CONTACT","+61 3 8736 1750","info@veritusresearch.com",{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100616566",false,"NCT07307274","A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults","A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity","Inclusion Criteria:\n\n* Must be able to understand the full nature and purpose of the study, including possible risks and adverse effects.\n* Adult males and females, 18 to 55 years of age (inclusive) at screening.\n* Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities.\n* Have suitable venous access for blood sampling.\n* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n\nExclusion Criteria:\n\n* Known hypersensitivity to the study drug or any of the study drug ingredients.\n* History of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer's ability to participate in the study.\n* History or presence of CS cardiovascular, pulmonary, hepatic, renal, haematological, endocrine, immunologic, dermatologic, psychiatric, or neurological disease\u002Fdisorder, including any acute illness, within the past 3 months determined by the PI (or delegate) to be clinically relevant.",true,"ALL","18 Years","55 Years",{"count":60,"type":61},64,"ESTIMATED","INTERVENTIONAL",[64],"PHASE1","A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.",[67,68],"Healthy","Overweight and Obese Adults","2026-04-28",{"date":71,"type":72},"2026-04-29","ACTUAL",{"date":74,"type":72},"2026-01-13",{"date":76,"type":61},"2026-12-31",{"name":5,"class":6},1]